Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04784364 · ClinicalTrials.gov registry record

Biologics And Clinical Immunology Cohort at Sinai

A clinical trial of Autoimmune Diseases and Primary Immune Deficiency, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
800
Enrollment target
1
Study location

NCT04784364: Recruiting study of Autoimmune Diseases and Primary Immune Deficiency, sponsored by Icahn School of Medicine at Mount Sinai.

NCT04784364 is a study of Autoimmune Diseases and Primary Immune Deficiency that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 800 participants, below the 946-participant average among 25 other Autoimmune Diseases trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04784364, a study of Autoimmune Diseases and Primary Immune Deficiency, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
800 participants
Enrollment target
1
Study location

Study Summary

The study team plans to establish a bioregistry of patients receiving biologic therapy as part of their standard treatment at the Mount Sinai Therapeutic Infusion Center and affiliated practices. The study team will to apply state-of-the-art approaches to assessing and predicting immunological and clinical responses associated with these standards and prescribed treatments. The approach is twofold. The first component is to establish a robust and flexible biorepository and database that includes demographic, immunologic, exposure and clinical records, and can facilitate research across disciplines, and across other registries affiliated with Mount Sinai. The second component is to address specific key research questions focused on using novel diagnostics to increase the effectiveness of biologic treatment. Most patients will be recruited from the Mount Sinai Therapeutic Infusion Center (TIC), although others receiving infusions elsewhere or at home will be recruited from outpatient Sinai affiliated clinical practices.

Primary Outcome

Establish a bioregistry of patients receiving biologic therapy as part of their standard treatment at the Mount Sinai Therapeutic Infusion Center and affiliated practices. The approach is twofold. The first component is to establish a robust and flexible biorepository and database that includes demographic, immunologic, exposure and clinical records, and can facilitate research across disciplines, and across other registries affiliated with Mount Sinai. The second component is to address specifi

Study Locations (1)

New York

  • Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2021-03-03
Est. Completion 2030-11

What NCT04784364 shows while recruiting

NCT04784364 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, below the 946-participant average among 25 other Autoimmune Diseases trials with a reported enrollment target (15% lower).

The record links to 3 conditions, with Autoimmune Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT04784364 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04784364 about?

NCT04784364 is a clinical study titled "Biologics And Clinical Immunology Cohort at Sinai". The study team plans to establish a bioregistry of patients receiving biologic therapy as part of their standard treatment at the Mount Sinai Therapeutic Infusion Center and affiliated practices. The study team will to apply state-of-the-art approaches to assessing and predicting immunological and c...

What is the current status of trial NCT04784364?

This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2021-03-03. Estimated completion is 2030-11.

What conditions does trial NCT04784364 study?

This clinical trial studies the following conditions: Autoimmune Diseases, Primary Immune Deficiency, Immunological Disease.

Who is sponsoring clinical trial NCT04784364?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04784364 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autoimmune Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04784364's enrollment target sits among peer trials

800 7th of 25 higher than 19 of 25 other Autoimmune Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autoimmune Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00695214 · 800 participants · Phase 2

    Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea

  • NCT03048201 · 800 participants · NA

    Physica System Total Knee Replacement Registry Study

  • NCT03792659 · 800 participants

    The EXPLORE MG Registry for Myasthenia Gravis

  • NCT03819296 · 800 participants · Phase 1

    Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04784364, the US trial registry maintained by the National Library of Medicine. NCT04784364 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.